NCT03797651

Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial

Status unknown NA Last updated 7 March 2023

What this trial tests

NA trial testing Standard DAPT in Coronary Artery Disease, Acute Coronary Syndrome in 2,850 participants. Status unknown.

Timeline

24 April 2019

Primary endpoint
4 April 2025

4 April 2025

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2,850
Start date	24 April 2019
Primary completion	4 April 2025
Estimated completion	4 April 2025
Sites	1 location across South Korea

Drugs / interventions tested

• Standard DAPT — full drug profile →
• Very-short DAPT less than 1 month after PCI — full drug profile →

Conditions studied

• Coronary Artery Disease, Acute Coronary Syndrome — all drugs for Coronary Artery Disease, Acute Coronary Syndrome →

Sponsor

Yonsei University

Who can join

Adults 19 to 80, any sex, with Coronary Artery Disease, Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events without aspirin after PCI in patients with acute coronary syndrome(ACS). Moreover, ticagrelor monotherapy will reduce bleeding risk compared to DAPT with aspirin plus ticagrelor. We will also evaluate 1-year safety and efficacy of Orsiro stent for patient with acute coronary syndrome. After confirmation of enrollment, patients will be randomized to continue standard treatment (aspirin plus ticagrelor) for 1 year or to stop aspirin after discharge or less than 1 month after PCI (ticagrelor monotherapy). Randomization will be stratified according to 1) the presence of diabetes and 2) ST elevation myocardial infarction (MI). Baseline clinical and angiographic characteristics, laboratory findings will be assessed at the time of randomization. All patients will provide informed consent on their own initiative.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
   Hong SJ, Lee SJ, Suh Y, Yun KH, et al · · 2024 · cited 90× · PMID 37878786 · DOI 10.1161/circulationaha.123.066943
2. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
   Guedeney P, Mesnier J, Sorrentino S, Abcha F, et al · · 2020 · cited 8× · PMID 32138287 · DOI 10.3390/jcm9030680
3. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.
   Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2025 · cited 6× · PMID 40058879 · DOI 10.1093/ehjcvp/pvaf012
4. Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how.
   Muthspiel M, Kaufmann CC, Burger AL, Panzer B, et al · · 2022 · cited 3× · PMID 36440022 · DOI 10.3389/fcvm.2022.1008194
5. Optimal timing of aspirin discontinuation with ticagrelor monotherapy in acute coronary syndrome: a post hoc comparative analysis from the TICO and T-PASS trials.
   Lee JH, Lee J, Kim SY, Jeon HS, et al · · 2026 · PMID 41697655 · DOI 10.4244/eij-d-25-00832